Subscribe to Newsletter
Diagnostics Screening and monitoring, Analytical science, Omics

A Breath of Fresh Air

Testing for drug use and disease is often complicated – blood and urine samples can be invasive, difficult to collect and easy to tamper with, especially in the field. Unfortunately, there’s no reliable alternative at the moment. But soon there might be: your breath.

The sampling of particles in exhaled breath is noninvasive, relatively easy to perform, and can be supervised to avoid tampering. However, it is still a new methodology in need of further research, which is why researchers at the University of Gothenburg, Sweden, decided to investigate two different sampling principles (1). The first is the PExA method, which is based on impaction and is designed to collect 0.5–7 μm particles from the small airways. The second method is based on filtration and collects particles of all sizes, including those formed during exhalation in the central or upper airways and oral cavity. Lead author Göran Ljungkvist explains…

“The more specific PExA method was originally designed for the collection of disease biomarkers. Using exhaled breath for that task poses an interesting analytical challenge: the limited amount of sample (on the order of 100 ng). In our research group, we analyze some of the important constituents of the lining fluid of the airways – for instance, surfactant protein A and the major surfactant lipids. PExA isn’t just limited to those molecules, though; it can be used to explore many other possible markers of disease. And because it’s noninvasive and easy for the patient (unlike bronchoalveolar lavage or induced sputum), the sampling can be performed repeatedly to monitor disease status, medication efficacy, or treatment compliance. PExA also allows us, for the first time, to sample disease markers from the active site in small airway diseases – facilitating screening and early detection.

“The PExA instrument is already commercially available and used by research groups all over the world. Our next steps? First, we need to validate biomarkers of the disease of interest. Then, ideally, we’d like to make the analytical testing either sensor-based or performed by something cheaper and less complex than, for instance, a mass spectrometer. Finally, we’d also like to miniaturize the sampler. The timeline for these steps is difficult to predict – it will depend on the disease of interest and the validation of the biomarker. The most exciting part? The ability to perform research on exhaled particles opens up a new range of possibilities for diagnostics and monitoring – initially of airway diseases, but eventually perhaps many others as well.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. G Ljungkvist et al., “Two techniques to sample non-volatiles in breath – exemplified by methadone“, J Breath Res, 12, 016011 (2017). PMID: 29220343.
About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Related Application Notes
The Development of Plasma Amyloid-β Assay and its Significance in Alzheimer’s Disease

| Contributed by Shimadzu

The Future of Noninvasive Multi-Cancer Screening

| Contributed by Horizon Discovery

NEXTFLEX Variant-Seq™ SARS-CoV-2 Kit

| Contributed by Revvity

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine